Meeting
2017 ASCO Annual Meeting
SANDPIPER: Phase III study of the PI3-kinase (PI3K) inhibitor taselisib (GDC-0032) plus fulvestrant in patients (pts) with estrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancer (BC) enriched for pts with PIK3CA-mutant tumors.
Authors
Jose Baselga
Memorial Sloan Kettering Cancer Center, New York, NY
Jose Baselga , Javier Cortés , Michelino DeLaurentiis , Susan Dent , Véronique Diéras , Nadia Harbeck , Jerry Y. Hsu , Huan Jin , Frauke Schimmoller , Timothy R. Wilson , Young-Hyuck Im , William Jacot , Ian E Krop , Sunil Verma
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Metastatic
Track
Breast Cancer
Sub Track
Hormone Receptor-Positive
Clinical Trial Registration Number
NCT02340221
Citation
J Clin Oncol 35, 2017 (suppl; abstr TPS1119)
DOI
10.1200/JCO.2017.35.15_suppl.TPS1119
Abstract #
TPS1119
Poster Bd #
104b
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
SANDPIPER: Phase III study of the PI3-kinase (PI3K) inhibitor taselisib (GDC-0032) plus fulvestrant in patients (pts) with estrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancer (BC) enriched for pts with PIK3CA-mutant tumors.
First Author: Jose Baselga
Poster
2015 ASCO Annual Meeting
SANDPIPER: Phase III study of the PI3-kinase (PI3K) inhibitor taselisib (GDC-0032) plus fulvestrant in patients (pts) with estrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancer (BC) enriched for pts with PIK3CA mutant tumors.
First Author: Jose Baselga
Poster
2023 ASCO Annual Meeting
INAVO121: Phase III study of inavolisib (INAVO) + fulvestrant (FUL) vs. alpelisib (ALP) + FUL in patients (pts) with hormone receptor-positive, HER2-negative (HR+, HER2–) PIK3CA‑mutated (mut) locally advanced or metastatic breast cancer (LA/mBC).
First Author: Dejan Juric
Poster
2016 ASCO Annual Meeting
A phase II study of the PI3K inhibitor taselisib (GDC-0032) combined with fulvestrant (F) in patients (pts) with HER2-negative (HER2-), hormone receptor-positive (HR+) advanced breast cancer (BC).
First Author: Maura N. Dickler